Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.

[1]  N. Watts,et al.  Long-term use of bisphosphonates in osteoporosis. , 2010, The Journal of clinical endocrinology and metabolism.

[2]  T. Powles,et al.  Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. , 2010, European journal of cancer.

[3]  H. Meyer,et al.  Change in the use of hormone replacement therapy and the incidence of fracture in Oslo , 2009, Osteoporosis International.

[4]  P. Delmas,et al.  Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis , 2008, Osteoporosis International.

[5]  J. Reginster,et al.  Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women , 2008, Osteoporosis International.

[6]  N. Kohno.  Treatment of breast cancer with bone metastasis: bisphosphonate treatment — current and future , 2008, International Journal of Clinical Oncology.

[7]  A. Genazzani,et al.  Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. , 2008, Maturitas.

[8]  Alan Bensoussan,et al.  Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis , 2007, The Lancet.

[9]  A. Çetin,et al.  Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis , 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[10]  John Brazier,et al.  Clodronate Reduces the Incidence of Fractures in Community‐Dwelling Elderly Women Unselected for Osteoporosis: Results of a Double‐Blind, Placebo‐Controlled Randomized Study , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  W. Sheu,et al.  Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women. , 2006, Metabolism: clinical and experimental.

[12]  L. Niskanen,et al.  Cross-calibration of Lunar DPX-IQ and DPX dual-energy x-ray densitometers for bone mineral measurements in women: effect of body anthropometry. , 2005, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[13]  Gleb Haynatzki,et al.  Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women. , 2004, The Journal of clinical endocrinology and metabolism.

[14]  Krista F. Huybrechts,et al.  The impact of compliance with osteoporosis therapy on fracture rates in actual practice , 2004, Osteoporosis International.

[15]  V. Beral,et al.  Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. , 2004, JAMA.

[16]  J. Kanis,et al.  Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double‐Blind, Placebo‐Controlled 3‐Year Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[18]  C. Christiansen,et al.  Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. , 2004, Bone.

[19]  M. Välimäki,et al.  Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. , 2004, The Journal of clinical endocrinology and metabolism.

[20]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[21]  P. Delmas,et al.  Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study. , 2003, Bone.

[22]  R. Parker,et al.  Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. , 2003, JAMA.

[23]  G. Guyatt,et al.  V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women , 2002 .

[24]  F. Orio,et al.  Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[25]  J. Mönkkönen,et al.  The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. , 2001, Arthritis and rheumatism.

[26]  D. Torgerson,et al.  Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. , 2001, JAMA.

[27]  S. Daya,et al.  Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. , 2000, Human reproduction.

[28]  R. Recker,et al.  Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[29]  R. Lindsay,et al.  Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. , 1999, The Journal of clinical endocrinology and metabolism.

[30]  R. Honkanen,et al.  HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. , 1998, Maturitas.

[31]  K. Savolainen,et al.  Two‐site enzyme immunoassay for measuring intact human osteocalcin in serum , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  R. Honkanen,et al.  Osteoporosis risk factors, gynaecological history and fractures in perimenopausal women--the results of the baseline postal enquiry of the Kuopio Osteoporosis Risk Factor and Prevention Study. , 1993, Maturitas.

[33]  N. Niikura,et al.  Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer , 2010 .

[34]  N. Watts,et al.  Long-Term Use of Bisphosphosphonates in Osteoporosis , 2010 .

[35]  F. Drobniewski,et al.  Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women : systematic review and meta-analysis , 2008 .

[36]  H. Bone,et al.  Combining Bisphosphonates with Hormone Therapy for Postmenopausal Osteoporosis , 2004, Treatments in endocrinology.

[37]  G. Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. , 2002, Endocrine reviews.

[38]  G. Guyatt,et al.  Meta-Analyses of Therapies for Postmenopausal Osteoporosis , 2002 .